

MOLECULAR CANCER DIAGNOSTIC FOR SOLID TUMORS

OncoGxOne™ analyzes a patient's tumor for genetic mutations found in cancers.

- Profiles clinically relevant mutations in 56 genes to guide the selection of targeted therapies
- Assays 8 genes with pharmacogenomics (PGx) information to help predict response to chemotherapies
- Detects all mutation types, including SNV, Indel, gene fusion, and CNV
- Average depth of coverage exceeds 250x resulting in mutation detection with high specificity and sensitivity

Targeted Therapies Available for Cancer Subtypes

Brain Cancer

- Glioma
- Medulloblastoma

Breast Cancer

Digestive System

- Colorectal Cancer
- Esophageal Cancer
- Gastrointestinal Stromal Tumor (GIST)

Gynecological

- Endometrial Cancer
- Ovarian Cancer
- Squamous Cell Cervical Cancer

Lung Cancer

- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer

Neuroblastoma

Renal Cell Carcinoma Sarcoma

- Liposarcoma
- Rhabdomyosarcoma

Skin Cancer

- Basal Cell Carcinoma
- Melanoma

Prostate Cancer


Thyroid Cancer

OncoGxOne™ Gene List

ABL1	CEBPA	GNAQ	NPM1
AKT1	CRLF2	HRAS	NRAS
ALK	CTNNB1	IDH1	PDGFRA
ATM	DDR2	IDH2	PDGFRB
AURKA	DNMT3A	JAK1	PIK3CA
BCL2	EGFR	JAK2	PTCH1
BCL6	ERBB2	KIT	PTEN
BCR	ESR1	KMT2A	RARA
BRAF	ETV6	KRAS	RET
BRCA1	FGFR1	MAP2K1	ROS1
BRCA2	FGFR2	MET	RUNX1
CCND1	FGFR3	MPL	SMO
CCNE1	FLT3	MYC	TP53
CDK4	GNA11	NF1	TSC1
CYP2C8	DYPD	TPMT	UGT1A1
CYP2D6	MTHFR	TYMS	XRCC1

PGx Genes

Proprietary Bioinformatics Analysis



Interpretation Powered by N-of-One

- Industry leading clinical interpretation
- Most up-to-date scientific and clinical evidence
- Incorporates relevant guidelines
- Clinical trial match with location prioritization



USA FDA-Approved Targeted Therapies

Ado-trastuzumab emtansine (Kadcyla®)	Goserelin (Zoladex®)	Regorafenib (Stivarga®)
Afatinib (Gilotrif®)	Imatinib (Gleevec®)	Ruxolitinib (Jakafi®)
Alectinib (Alecensa®)	Ipilimumab (Yervoy®)	Sirolimus (Rapamune®)
Anastrozole (Arimidex®)	Lapatinib (Tykerb®)	Sorafenib (Nexavar®)
Bosutinib (Bosulif®)	Lenvatinib (Lenvima®)	Sunitinib (Sutent®)
Cabozantinib (Cometriq®)	Letrozole (Femara®)	Tamoxifen (Soltamox®; Nol-vadex®)
Ceritinib (Zykadia®)	Leuprolide (Lupron®; Eligard®)	Temsirolimus (Torisel®)
Cetuximab (Erbix®)	Nilotinib (Tasigna®)	Tofacitinib (Xeljanz®)
Cobimetinib (Cotellic®)	Nintedanib (OFEV®)	Toremifene (Fareston®)
Crizotinib (Xalkori®)	Nivolumab (Opdivo®)	Trametinib (Mekinist®)
Dabrafenib (Tafinlar®)	Olaparib (Lynparza®)	Trastuzumab (Herceptin®)
Dasatinib (Sprycel®)	Osimertinib (Tagrisso®)	Tretinoin; ATRA (Vesanoid®)
Erlotinib (Tarceva®)	Palbociclib (Ibrance®)	Vandetanib (Caprelsa®)
Everolimus (Zortress®; Afinitor®)	Panitumumab (Vecti-bix®)	Vemurafenib (Zelboraf®)
Exemestane (Aromasin®)	Pazopanib (Votrient®)	Vismodegib (Erivedge®)
Fulvestrant (Faslodex®)	Pertuzumab (Perjeta®)	
Gefitinib (Iressa®)	Ponatinib (Iclusig®)	

USA FDA-Approved Chemotherapies

Arsenic trioxide (Trisenox®)	Docetaxel (Taxotere®)	Paclitaxel (Onxol®; Abraxane®)
Capecitabine (Xeloda®)	Fluorouracil (5-FU®)	Mercaptopurine (Purinethol®)
Carboplatin (Paraplatin®)	Irinotecan (Camptosar®)	Thioguanine (Tabloid®)
Cisplatin (Platinol®)	Leucovorin (Wellcovorin®)	
Cyclophosphamide (Endoxan®)	Oxaliplatin (Eloxatin®)	

Selected Drugs in Clinical Trials

Crenolanib (CP-868-596)	Ganetespib (STA-9090)	Retaspimycin (IPI-504)
Dacomitinib (PF-00299804)	Neratinib (HKI-272)	Rociletinib (CO-1686)
Dinaciclib (SCH-727965)	Quizartinib (AC220)	Selumetinib (AZD6244)
Dovitinib (TKI258)	Refametinib (BAY86-9766)	Tanespimycin (17-AAG)

Testing and interpretation performed by Admera Health LLC · 126 Corporate Boulevard, South Plainfield, New Jersey, USA 07080 · OncoGxOne™ is a trademark of Admera Health. LLC.